or Try an Advanced Search...

    Technical Analysis for TPST - Tempest Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.90 3.85% 0.03
    TPST closed up 3.85 percent on Wednesday, November 20, 2024, on 26 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical TPST trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 3.85%
    Wide Bands Range Expansion 3.85%
    Lower Bollinger Band Touch Weakness 3.85%
    Oversold Stochastic Weakness 3.85%
    MACD Bearish Signal Line Cross Bearish 5.96%
    Older End-of-Day Signals for TPST ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 18 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Up 5% about 22 hours ago
    Gap Up Closed about 22 hours ago
    Down 2 % about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    TPST Chart by TradingView
    Basic chart:

    Profile

    Tempest Therapeutics, Inc. Description

    Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Tumor

    Is TPST a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Tempest Therapeutics GAAP EPS of -$0.41 misses by $0.05
    Nov 12 Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
    Nov 12 Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
    Oct 30 Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Oct 10 Roche collaboration for lead asset boosts Tempest
    Oct 10 Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
    Oct 10 Tempest Extends Limited Duration Stockholder Rights Plan
    Sep 20 Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Sep 18 Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
    Sep 5 Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    See more TPST news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.0
    52 Week Low 0.8
    Average Volume 3,962,684
    200-Day Moving Average 2.43
    50-Day Moving Average 1.16
    20-Day Moving Average 0.99
    10-Day Moving Average 0.98
    Average True Range 0.11
    RSI (14) 37.89
    ADX 12.21
    +DI 19.80
    -DI 27.96
    Chandelier Exit (Long, 3 ATRs) 0.89
    Chandelier Exit (Short, 3 ATRs) 1.12
    Upper Bollinger Bands 1.17
    Lower Bollinger Band 0.82
    Percent B (%b) 0.22
    BandWidth 34.52
    MACD Line -0.07
    MACD Signal Line -0.07
    MACD Histogram -0.0063
    Fundamentals Value
    Market Cap 17.29 Million
    Num Shares 19.2 Million
    EPS -2.20
    Price-to-Earnings (P/E) Ratio -0.41
    Price-to-Sales 0.00
    Price-to-Book 8.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.00
    Resistance 3 (R3) 1.00 0.95 0.99
    Resistance 2 (R2) 0.95 0.93 0.96 0.98
    Resistance 1 (R1) 0.93 0.91 0.90 0.93 0.97
    Pivot Point 0.88 0.88 0.87 0.89 0.88
    Support 1 (S1) 0.86 0.86 0.83 0.86 0.82
    Support 2 (S2) 0.81 0.84 0.82 0.82
    Support 3 (S3) 0.79 0.81 0.81
    Support 4 (S4) 0.79